Marco Ruella, MD

Selected Publications

• Monette A, Aguilar-Mahecha A, Altinmakas E, Angelos MG, Assad N, Batist G, Bommareddy PK, Bonilla DL, Borchers CH, Church SE, Ciliberto G, Cogdill AP, Fattore L, Hacohen N, Haris M, Lacasse V, Lie WR, Mehta A, Ruella M, Sater S, Spatz A, Taouli B, Tarhoni I, Gonzalez-Kozlova E, Tirosh I, Wang X, Gnjatic S. : The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy- and Radiomics-Based Technologies for Immuno-oncology Biomarker Discovery and Application. Clin Cancer Res. 31(12) : 2278-2293, June 2025 Notes: doi: 10.1158/1078-0432.CCR-24-3791.
• Sullivan RJ, Cillo AR, Ferris RL, Jenkins RW, Kluger HM, Kok M, Lipson EJ, Paruzzo L, Redmond WL, Ruella M, Schalper KA, Thommen DS, Tolley K, Yarchoan M, Garnett-Benson C. : SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy. J Immunother Cancer. June 2025 Notes: doi: 10.1136/jitc-2025-011929.
• Lϋӧnd F, Whalen J, Song Y, Schriefer K, Newcombe R, Orlando EJ, Choi SM, Ruella M, Fraietta JA, Schuster SJ, Brogdon JL, Niederst MJ, Treanor LM. : DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response. Blood Cancer Discov. June 2025 Notes: doi: 10.1158/2643-3230.BCD-24-0176.
• Ahmed SO, El Fakih R, Kharfan-Dabaja MA, Syed F, Mufti G, Chabannon C, Rondelli D, Mohty M, Al Ahmari AA, Gauthier J, Ruella M, Perales MA, Hashmi S, Alfraih F, Ghorashian S, Alzahrani M, Abba Z, Koh M, Pasquini M, Ruggeri A, Garderet L, Albabtain A, Weisdorf D, Greinix H, Samarkandi H, Hamad N, Atsuta Y, Hamadani M, Hari P, Majhail NS, Greco R, Alzahrani H, Sureda A, Yakoub-Agha I, Alahmari AD, Niederwieser D, Aljurf M. : Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation. Transplant Cell Ther. May 2025 Notes: doi: 10.1016/j.jtct.2025.05.012.
• Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH. : Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure N Engl J Med 392 : 1824-1835, May 2025
• Luciani F, Safavi A, Guruprasad P, Chen L, Ruella M. : Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges. Blood Cancer Discov. 6(3) : 159-162, May 2025 Notes: doi: 10.1158/2643-3230.BCD-23-0240.
• Stefan K. Barta, Stephen J. Schuster, Jakub Svoboda, Jordan Spencer Carter, Elise A. Chong, Daniel J. Landsburg, Sunita Dwivedy Nasta, Ruchi Patel, Joseph A. Fraietta, Colin Thomas, Aditya Nimmagadda, Lavanya Peddada, Adam Snook, Nicholas Anthony Siciliano, Ruella M, and Rosemary Mazanet. : CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T-cell non-Hodgkin lymphoma: A first-in-human phase I clinical trial (NCT06420089). Journal of Clinical Oncology 43(16) May 2025 Notes: https://doi.org/10.1200/JCO.2025.43.16_suppl.TPS7087
• Thomas Luo, Luca Paruzzo, Sandra P. Susanibar Adaniya, Alfred L. Garfall, Matthew Ho, Shivani Kapur, Ruella M, Edward Allen Stadtmauer, Federico Stella, Dan T. Vogl, Adam J. Waxman, and Adam D. Cohen. : Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology 43(16) May 2025 Notes: https://doi.org/10.1200/JCO.2025.43.16_suppl.7518
• Paruzzo L, Ruella M. : CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India. Lancet Haematol. 12(4) : e236-e238, April 2025 Notes: doi: 10.1016/S2352-3026(25)00040-7.
• Fiore D, Cappelli LV, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A, Han X, Taylor A, Chiu W, Fragliasso V, Tabbo F, Zamponi N, Di Siervi N, Kayembe C, Medico G, Patel RP, Gaudiano M, Machiorlatti R, Astone G, Cacciapuoti MT, Zanetti G, Pignataro C, Eric RA, Patel S, Zammarchi F, Zanettini C, Queiroz L, Nikitina A, Kudryashova O, Karelin A, Nikitin D, Tychinin D, Postovalova E, Bagaev A, Svekolkin V, Belova E, Tikhonova K, Degryse S, Xu C, Novero D, Ponzoni M, Tiacci E, Falini B, Song J, Khodos I, De Stanchina E, Macari G, Cafforio L, Gardini S, Piva R, Medico E, Ng SY, Moskowitz A, Epstein Z, Intlekofer A, Ahmed D, Chan WC, Martin P, Ruan J, Bertoni F, Foà R, Brody JD, Weinstock DM, Osan J, Santambrogio L, Elemento O, Betel D, Tam W, Ruella M, Cerchietti L, Rabadan R, Horwitz S, Inghirami G. : A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities. Cell Rep Med. 6(4) April 2025 Notes: doi: 10.1016/j.xcrm.2025.102029.